Anthrax laboratory findings: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(33 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Anthrax}}
{{Anthrax}}
{{CMG}}
{{CMG}}; {{AE}} {{JS}}


==Overview==
==Overview==
Initial evaluation of patients suspected of having anthrax should be similar to the standard evaluation for patients with an acute [[febrile]] illness and should have an emphasis on obtaining pre-treatment blood and other appropriate cultures.<ref name=CDC>{{cite web | title = Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults | url = http://wwwnc.cdc.gov/eid/article/20/2/13-0687_article }}</ref>  When systemic anthrax is present, abnormalities in laboratory tests include [[anemia]], [[thrombocytopenia]], and [[leukocytosis]] particularly in the latter stages of the disease.  Other laboratory findings are [[hyponatremia]], increased [[BUN]], elevated [[transaminase]] levels, [[hypoalbuminemia]], and elevated [[troponin]].  Cell cultures from the initial skin lesion, [[blood]], [[CSF]], or [[pleural fluid]] can identify the [[Bacillus anthracis|organism]] and possibly the [[toxins]].  In injection anthrax, the typical laboratory finding is an [[inflammatory]] pattern with a low [[CRP]].  A normal [[PT]]/[[PTT]] at admission does not exclude [[coagulopathy]] nor [[DIC]].


==Laboratory Findings==
==Laboratory Findings==
The following tests are used in the diagnosis and monitoring of systemic anthrax:<ref name="HendricksWright2014">{{cite journal|last1=Hendricks|first1=Katherine A.|last2=Wright|first2=Mary E.|last3=Shadomy|first3=Sean V.|last4=Bradley|first4=John S.|last5=Morrow|first5=Meredith G.|last6=Pavia|first6=Andy T.|last7=Rubinstein|first7=Ethan|last8=Holty|first8=Jon-Erik C.|last9=Messonnier|first9=Nancy E.|last10=Smith|first10=Theresa L.|last11=Pesik|first11=Nicki|last12=Treadwell|first12=Tracee A.|last13=Bower|first13=William A.|title=Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults|journal=Emerging Infectious Diseases|volume=20|issue=2|year=2014|issn=1080-6040|doi=10.3201/eid2002.130687}}</ref>
Show below is a table depicting the tests are used in the [[diagnosis]] and monitoring of systemic [[anthrax]].<ref name="HendricksWright2014">{{cite journal|last1=Hendricks|first1=Katherine A.|last2=Wright|first2=Mary E.|last3=Shadomy|first3=Sean V.|last4=Bradley|first4=John S.|last5=Morrow|first5=Meredith G.|last6=Pavia|first6=Andy T.|last7=Rubinstein|first7=Ethan|last8=Holty|first8=Jon-Erik C.|last9=Messonnier|first9=Nancy E.|last10=Smith|first10=Theresa L.|last11=Pesik|first11=Nicki|last12=Treadwell|first12=Tracee A.|last13=Bower|first13=William A.|title=Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults|journal=Emerging Infectious Diseases|volume=20|issue=2|year=2014|issn=1080-6040|doi=10.3201/eid2002.130687}}</ref>


{| style="border: 2px solid #DCDCDC; font-size: 90%"
{| style="border: 2px solid #DCDCDC; font-size: 90%"
|+ '''Laboratory findings'''
|+ '''Laboratory findings'''
|-
|-
! style="width: 100px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Test}}
! style="width: 150px; background: #4479BA; text-align: center;"|{{fontcolor|#FFF|Test}}
! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF| Initial Findings}}
! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF|Initial Findings}}
! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF| Serial Monitoring}}
! style="width: 200px; background: #4479BA; text-align: center;"| {{fontcolor|#FFF|Serial Monitoring}}
|-
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[CBC]]'''
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''CBC'''
| style="background: #DCDCDC; padding: 5px;"| [[Hemoconcentration]]<br>Possible [[Thrombocytopenia]]<br>[[Leukocyte]] count commonly normal
| style="background: #DCDCDC; padding: 5px;"| [[Hemoconcentration]]<br>Possible [[thrombocytopenia]]<br>[[Leukocyte]] count commonly normal
| style="background: #DCDCDC; padding: 5px;"| [[Anemia]]<br>[[Thrombocytopenia]]<br>[[Leukocytosis]] (late in disease)
| style="background: #DCDCDC; padding: 5px;"| [[Anemia]]<br>[[Thrombocytopenia]]<br>[[Leukocytosis]] (late in disease)
|-
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Electrolyte]], [[Renal]] Panel, [[Lactate]] Level'''
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Electrolyte<br>Renal Panel'''
| style="background: #DCDCDC; padding: 5px;"| Decreased [[Na+]] level<br>Increased [[BUN]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Decreased sodium level<br>Increased [[BUN]]
| style="background: #DCDCDC; padding: 5px;"|
|-
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Liver]] Enzymes, Serum [[Albumin]]'''
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Liver Enzymes<br>Serum Albumin'''
| style="background: #DCDCDC; padding: 5px;"|Elevated [[transaminase]] levels<br>[[hypoalbuminemia]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Elevated [[transaminase]] levels<br>[[Hypoalbuminemia]]
| style="background: #DCDCDC; padding: 5px;"|
|-
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[PT]], [[PTT]], [[D-dimer]], [[Fibrinogen]]'''
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''PT<br>PTT<br>D-dimer<br>Fibrinogen'''
| style="background: #DCDCDC; padding: 5px;"| Normal [[PT]]/[[PTT]] does not exclude [[DIC]] or [[coagulopathy]]
| style="background: #DCDCDC; padding: 5px;"| Normal [[PT]]/[[PTT]] does not exclude [[DIC]] or [[coagulopathy]]
| style="background: #DCDCDC; padding: 5px;"| Low threshold for hypercoagulability workup:<br>[[Haptoglobin]]<br>[[LDH]]<br>[[Fibrin]] split products<br>ADAMTS 13 if [[hemolytic anemia]]  
| style="background: #DCDCDC; padding: 5px;"| Low threshold for hypercoagulability workup:<br>[[Haptoglobin]]<br>[[LDH]]<br>[[Fibrin]] split products<br>ADAMTS 13 if [[hemolytic anemia]]  
|-
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[C-Reactive Protein]]'''
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''C-Reactive Protein'''
| style="background: #DCDCDC; padding: 5px;"| Characterization of Inflammatory Response<br>Typically low [[CRP]] in injection [[anthrax]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Characterization of inflammatory response<br>Typically low [[CRP]] in injection [[anthrax]]
| style="background: #DCDCDC; padding: 5px;"|
|-
 
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Gram stain<br>Cultures<br>Toxic Assays'''<br><span style="font-size:90%">([[Blood]], [[serum]], [[CSF]], [[pleural fluid]], [[ascites]], wound [[exudate]]*, bronchial [[exudate]])</span>
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| Cultures usually negative after [[antibiotics]]<br>[[Toxins]] may be detected
|-
|-
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''[[Gram Stain]], [[Cell cultures|Cultures]], Toxic Assays'''
| style="background: #F5F5F5; padding: 5px; text-align: center;"| '''Cardiac Enzymes<br>BNP'''
| style="background: #DCDCDC; padding: 5px;"| [[Blood]]<br>[[Serum]]<br>[[CSF]]<br>[[Pleural fluid]]<br>[[Ascites]]<br>Wound [[exudate]]<br>[[Bronchial]] [[exudate]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" colspan=2| [[Troponin]] leak caused by increased [[cardiac]] demand from [[infection]]<br>(particularly if [[atrial fibrillation]] with rapid [[ventricular]] response)
| style="background: #DCDCDC; padding: 5px;"| [[]]
|}
|}
<nowiki>*</nowiki> Note that topical swabs from skin lesions will not pick up [[B. anthracis]]. Detection in smears or by culture requires lifting the edge of the eschar with tweezers (this gives no pain unless there is secondary infection) and obtaining fluid from underneath. The fluid will probably be sterile if the patient has been treated with an [[antibiotic]].


==References==
==References==
Line 45: Line 46:
{{reflist|2}}
{{reflist|2}}


[[Category:Needs content]]
[[Category:Disease]]
[[Category:Bacterial diseases]]
[[Category:Biological weapons]]
[[Category:Livestock]]
[[Category:Zoonoses]]
[[Category:Medical disasters]]
[[Category:Emergency mdicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Dermatology]]
[[Category:Pulmonology]]
[[Category:Gastroenterology]]

Latest revision as of 20:25, 29 July 2020

Anthrax Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Anthrax from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anthrax laboratory findings On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anthrax laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anthrax laboratory findings

CDC on Anthrax laboratory findings

Anthrax laboratory findings in the news

Blogs on Anthrax laboratory findings

Directions to Hospitals Treating Anthrax

Risk calculators and risk factors for Anthrax laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Initial evaluation of patients suspected of having anthrax should be similar to the standard evaluation for patients with an acute febrile illness and should have an emphasis on obtaining pre-treatment blood and other appropriate cultures.[1] When systemic anthrax is present, abnormalities in laboratory tests include anemia, thrombocytopenia, and leukocytosis particularly in the latter stages of the disease. Other laboratory findings are hyponatremia, increased BUN, elevated transaminase levels, hypoalbuminemia, and elevated troponin. Cell cultures from the initial skin lesion, blood, CSF, or pleural fluid can identify the organism and possibly the toxins. In injection anthrax, the typical laboratory finding is an inflammatory pattern with a low CRP. A normal PT/PTT at admission does not exclude coagulopathy nor DIC.

Laboratory Findings

Show below is a table depicting the tests are used in the diagnosis and monitoring of systemic anthrax.[2]

Laboratory findings
Test Initial Findings Serial Monitoring
CBC Hemoconcentration
Possible thrombocytopenia
Leukocyte count commonly normal
Anemia
Thrombocytopenia
Leukocytosis (late in disease)
Electrolyte
Renal Panel
Decreased sodium level
Increased BUN
Liver Enzymes
Serum Albumin
Elevated transaminase levels
Hypoalbuminemia
PT
PTT
D-dimer
Fibrinogen
Normal PT/PTT does not exclude DIC or coagulopathy Low threshold for hypercoagulability workup:
Haptoglobin
LDH
Fibrin split products
ADAMTS 13 if hemolytic anemia
C-Reactive Protein Characterization of inflammatory response
Typically low CRP in injection anthrax
Gram stain
Cultures
Toxic Assays

(Blood, serum, CSF, pleural fluid, ascites, wound exudate*, bronchial exudate)
Cultures usually negative after antibiotics
Toxins may be detected
Cardiac Enzymes
BNP
Troponin leak caused by increased cardiac demand from infection
(particularly if atrial fibrillation with rapid ventricular response)

* Note that topical swabs from skin lesions will not pick up B. anthracis. Detection in smears or by culture requires lifting the edge of the eschar with tweezers (this gives no pain unless there is secondary infection) and obtaining fluid from underneath. The fluid will probably be sterile if the patient has been treated with an antibiotic.

References

  1. "Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults".
  2. Hendricks, Katherine A.; Wright, Mary E.; Shadomy, Sean V.; Bradley, John S.; Morrow, Meredith G.; Pavia, Andy T.; Rubinstein, Ethan; Holty, Jon-Erik C.; Messonnier, Nancy E.; Smith, Theresa L.; Pesik, Nicki; Treadwell, Tracee A.; Bower, William A. (2014). "Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults". Emerging Infectious Diseases. 20 (2). doi:10.3201/eid2002.130687. ISSN 1080-6040.